ALTASCIENCES
4.1.2022 16:02:05 CET | Business Wire | Press release
Altasciences , an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the U.S.A.
“This acquisition will add significant capacity and expertise to Altasciences’ existing preclinical offering ,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “Sinclair’s experience conducting research on a wide variety of species in a comprehensive range of drug classes will broaden our current preclinical offering and support Altasciences’ focus on providing our clients with customized solutions. ”
With over 80 animal rooms, Sinclair Research is a large nonclinical CRO in the U.S.A., providing full-service IND and NDA-enabling toxicology and safety pharmacology services. Built on more than 50 years of experience, Sinclair Research provides services to support biopharmaceutical, animal health, and medical device development programs. “We are very excited to be joining the Altasciences team, and look forward to being able to offer our preclinical services to a broader market by leveraging the resources and expertise of an integrated, global CRO,” stated Guy Bouchard, Chief Executive Officer at Sinclair Research.
“With this acquisition, Altasciences is continuing to advance its strategic growth plan to provide an expanded range of services in support of our integrated early-phase drug development solutions. Sinclair Research shares our commitment to animal welfare, and we look forward to merging our talents and working together with our new team of preclinical experts in the Midwest ,” added Chris Perkin, Altasciences’ Chief Executive Officer.
Fredrikson & Byron P.A. and Goodwin Procter LLP served as legal advisors to Altasciences on the transaction. Fairmount Partners acted as exclusive financial advisors to Sinclair Research, and Troutman Pepper acted as legal counsel.
About Altasciences
Altasciences
is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical
and clinical pharmacology
studies, including formulation, manufacturing, and analytical services
. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing
, clinical pharmacology and proof of concept
, bioanalysis
, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005683/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio2.3.2026 09:00:00 CET | Press release
Radiobotics to join Medimaps Group, creating a global provider of AI-driven musculoskeletal (MSK) medical imaging software The transaction is expected to close following receipt of Danish foreign direct investment (FDI) approval and other customary closing conditions Together, they will bridge the gap between preventative bone health and acute trauma diagnostics, offering an expanded portfolio across X-ray and DXA: Fracture detection, opportunistic bone fragility assessment, and fracture risk prediction The combined entity will have a commercial reach in 90 countries through a robust network of direct and partner channels Both organizations will maintain their established brands, supported by close R&D and commercial collaboration Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, and Radiobotics ApS, a leader in AI-powered MSK radiology solutions, today announced that they have entered into a strategic merger agreement. Closing of the transacti
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera2.3.2026 08:00:00 CET | Press release
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In addi
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants2.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the expansion of its 5G RedCap portfolio with the launch of the RM255C-GL for global markets and the RG255C-NA for the North America market, further strengthening its mid-tier 5G offering for worldwide deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301754857/en/ Quectel expands mid-tier 5G portfolio with new RedCap 3GPP release 17 variants As 5G expands further into industrial and IoT domains, the need for solutions that combine strong performance with cost efficiency is becoming increasingly critical. Positioned between high-speed eMBB and narrowband NB-IoT, 5G RedCap (Reduced Capability) has emerged as the ideal technology to address this mid-tier connectivity gap. With a comprehensive product portfolio and global deployment expertise, Quectel enables a seamless transition for mid-speed IoT applications moving toward sca
Thales sets a world first in quantum-safe security for 5G networks2.3.2026 08:00:00 CET | Press release
Thales has successfully demonstrated a world-first innovation that prepares 5G networks for the age of quantum computing, marking a major milestone for the global telecommunications industry. The collaboration with a top tier mobile operator, showed that existing 5G SIM / eSIM cards already deployed in the field can be securely upgraded to quantum-safe protection, without disrupting service or impacting the customer experience. This Post-Quantum Cryptographic (PQC) breakthrough proves that mobile networks can evolve their security through crypto agility to address quantum cyber threats. Quantum computing has the potential to break today’s encryption methods in the future, putting mobile communications, personal data and critical infrastructure at risk. For telecom operators, this is not a distant theoretical issue: 5G networks underpin everything from smartphones and connected vehicles to emergency services, industry and national infrastructure. This press release features multimedia.
NHOA Energy Announces Two Major MACSE Battery Projects2.3.2026 08:00:00 CET | Press release
The projects reinforce NHOA Energy’s leadership in the Italian market NHOA Energy, global provider of utility-scale energy storage systems, has been awarded two new Battery Energy Storage System (BESS) projects in Italy by a leading independent platform in the renewables and energy transition sector, with a total MACSE-contracted capacity of about 600 MWh and a total power of 90 MW. The two projects, located in Campania and Sardinia, represent NHOA Energy’s first systems awarded under MACSE (Meccanismo di Approvvigionamento di Capacità di Stoccaggio Elettrico), Italy’s new capacity mechanism dedicated to long-duration storage, and a milestone in the company’s growth in the national energy storage market. The projects, financed by a pool of top-tier Italian and international financial institutions, reaffirm NHOA Energy’s centrality as technology supplier and turnkey contractor in the Italian BESS market, built on extensive local and international experience, breadth of resources, intima
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom